AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
Humana updated its Medicare Advantage coverage policy, effective October 1, 2026, to apply LCD L40205 medical necessity criteria for NanoKnife IRE in intermediate-risk prostate cancer and certain liver tumors. The policy builds on Category I CPT codes 55877 and 47384 (effective January 1, 2026) and Palmetto GBA's final LCD, and Humana applies the criteria across MAC jurisdictions, covering roughly 7 million Medicare Advantage members.
Key figures
- Drug Name
- NanoKnife System (IRE)
- Cpt codes
- ["55877 (prostate tissue ablation)","47384 (liver tumor ablation)"]
- Humana members
- approximately 7 million
- Policy effective date
- October 1, 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.